Breaking News Instant updates and real-time market news.

GILT

Gilat Satellite

$5.38 /

+0.07 (+1.32%)

, CMTL

Comtech

$15.77 /

-0.14 (-0.88%)

13:52
09/08/20
09/08
13:52
09/08/20
13:52

Gilat granted temporary restraining order in fight with Comtech, Bloomberg says

GILT

Gilat Satellite

$5.38 /

+0.07 (+1.32%)

CMTL

Comtech

$15.77 /

-0.14 (-0.88%)

GILT Gilat Satellite
$5.38 /

+0.07 (+1.32%)

CMTL Comtech
$15.77 /

-0.14 (-0.88%)

06/04/20 Northland
Comtech price target lowered to $24 from $27 at Northland
03/31/20 Citi
Comtech price target lowered to $17 from $34 at Citi

TODAY'S FREE FLY STORIES

General news
FX Action: USD-CAD has posted a two-day low » 03:40
09/18/20
09/18
03:40
09/18/20
03:40

FX Action: USD-CAD has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
FX Update: The dollar has scraped out a two-day low » 03:20
09/18/20
09/18
03:20
09/18/20
03:20

FX Update: The dollar has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
Asian Market Update: » 01:35
09/18/20
09/18
01:35
09/18/20
01:35

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
U.S. leading index preview » 01:35
09/18/20
09/18
01:35
09/18/20
01:35

U.S. leading index…

U.S. leading index preview: the leading economic index likely rose 1.6% to 106.1 in August, which would be a fresh all-time high, following increases of 1.4% in July to 104.4 and 3.0% to 103.0 in June. These follow the huge drops of -6.3% in April to 97.0 and -7.5% in March to 103.5. Analysts expect gains in all of the 10 components except the leading credit index, with particularly big increases for the factory workweek, housing permits, consumer goods orders, and initial claims.

General news
U.S. consumer sentiment preview » 01:35
09/18/20
09/18
01:35
09/18/20
01:35

U.S. consumer sentiment…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
U.S. current account preview » 01:35
09/18/20
09/18
01:35
09/18/20
01:35

U.S. current account…

U.S. current account preview: the deficit is expected to widen sharply to -$177.2 B in Q2 after narrowing fractionally to -$104.2 B in Q1. Most of the erosion should come from trade where analysts estimate a -$164.9 B goods and services trade shortfall in Q2, versus -$119.1 B previously. As a percentage of nominal GDP, the gap is expected to nearly double to -3.6%, versus -1.9% in Q1. Analysts expect Q2 contraction rates for goods, services, and income of -66% for exports and -45% for imports, thanks to disruptions from COVID-19 for trade in goods and services, as well as income receipts and payments. Analysts expect an annual current account deficit of -$703 B in 2020, versus a high from the last expansion of -$498 B in 2019. The deficit remains below the -$806 B record deficit back in 2006.

Initiation
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts' » 21:13
09/17/20
09/17
21:13
09/17/20
21:13
RTRX

Retrophin

$19.67 /

-0.25 (-1.26%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico initiated coverage of Retrophin with an Outperform rating and $33 price target. The analyst believes sparsentan has potential to treat two kidney disorders, focal segmental glomerulosclerosis and IgA nephropathy, that currently lack effective therapies. Chico's estimates assign credit in both settings with fiscal 2027 revenue reaching $1.2B. With sparsentan advancing in two pivotal studies, "multiple value-creating catalysts" set for 2021, and a base business that provides downside protection, Retrophin shares offer an attractive risk/reward setup at current levels, Chico tells investors in a research note.

ShowHide Related Items >><<
RTRX Retrophin
$19.67 /

-0.25 (-1.26%)

09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
RTRX Retrophin
$19.67 /

-0.25 (-1.26%)

  • 09
    Jun
Upgrade
Kinross Gold upgraded to Outperform from Market Perform at BMO Capital » 21:12
09/17/20
09/17
21:12
09/17/20
21:12
KGC

Kinross Gold

$9.36 /

+0.03 (+0.32%)

BMO Capital analyst…

BMO Capital analyst Jackie Przybylowski upgraded Kinross Gold to Outperform from Market Perform with a price target of $14.25, up from $13.50. The company declared its first dividend since 2013, and it's a positive surprise at 3c share per quarter, Przybylowski tells investors in a research note. Further, the company will continue to use a $1,200 per ounce gold price assumption for its mine plans which is conservative in the current environment, adds the analyst. Przybylowski views this as a "major positive" and a sign of discipline. Today's update should resonate well with investors, says the analyst.

ShowHide Related Items >><<
KGC Kinross Gold
$9.36 /

+0.03 (+0.32%)

KGC Kinross Gold
$9.36 /

+0.03 (+0.32%)

09/11/20 National Bank
Kinross Gold price target raised to C$17 from C$16 at National Bank
08/05/20 BofA
Kinross Gold upgraded to Buy on valuation at BofA
08/05/20 BofA
Kinross Gold upgraded to Buy from Neutral at BofA
07/20/20 Scotiabank
Yamana downgraded to Sector Perform on valuation at Scotiabank
KGC Kinross Gold
$9.36 /

+0.03 (+0.32%)

KGC Kinross Gold
$9.36 /

+0.03 (+0.32%)

KGC Kinross Gold
$9.36 /

+0.03 (+0.32%)

Initiation
Krystal Biotech initiated with a Buy at B. Riley FBR » 20:43
09/17/20
09/17
20:43
09/17/20
20:43
KRYS

Krystal Biotech

$46.23 /

+ (+0.00%)

B. Riley FBR initiated…

B. Riley FBR initiated coverage of Krystal Biotech with a Buy rating and $100 price target.

ShowHide Related Items >><<
KRYS Krystal Biotech
$46.23 /

+ (+0.00%)

KRYS Krystal Biotech
$46.23 /

+ (+0.00%)

08/19/20 Chardan
Chardan sees valuation upside through 2022 for Krystal Biotech
03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
KRYS Krystal Biotech
$46.23 /

+ (+0.00%)

  • 19
    May
KRYS Krystal Biotech
$46.23 /

+ (+0.00%)

Upgrade
Fox Factory upgraded to Buy from Hold at Stifel » 20:42
09/17/20
09/17
20:42
09/17/20
20:42
FOXF

Fox Factory

$75.56 /

+2.36 (+3.22%)

Stifel analyst Jim Duffy…

Stifel analyst Jim Duffy upgraded Fox Factory to Buy from Hold with a $97 price target.

ShowHide Related Items >><<
FOXF Fox Factory
$75.56 /

+2.36 (+3.22%)

FOXF Fox Factory
$75.56 /

+2.36 (+3.22%)

07/15/20 Jefferies
Jefferies says Fox Factory absence on Bronco doesn't impair competitive position
07/14/20 Baird
Fox Factory down on Ford picking Bilstein for Bronco shocks, says Baird
06/16/20 CJS Securities
Fox Factory downgraded to Market Perform from Outperform at CJS Securities
05/29/20
Fly Intel: Top five analyst upgrades
FOXF Fox Factory
$75.56 /

+2.36 (+3.22%)

  • 18
    Jun
FOXF Fox Factory
$75.56 /

+2.36 (+3.22%)

Syndicate
Humanigen 8M share IPO priced at $8.50 » 20:40
09/17/20
09/17
20:40
09/17/20
20:40
HGEN

Humanigen

$0.00 /

+ (+0.00%)

JPMorgan and Jefferies…

JPMorgan and Jefferies acted as joint book running managers for the offering.

ShowHide Related Items >><<
  • 18
    Sep
Syndicate
Athira Pharma 12M share IPO priced at $17.00 » 20:38
09/17/20
09/17
20:38
09/17/20
20:38
ATHA

Athira Pharma

$0.00 /

+ (+0.00%)

The deal size was…

The deal size was increased to 12M shares of common stock from 10M shares of common stock and the deal priced at the high-end of the $15.00-$17.00 range. Goldman Sachs, Jefferies and Stifel acted as joint book running managers for the offering.

ShowHide Related Items >><<
  • 18
    Sep
Syndicate
Unity Software 25M share IPO priced at $52.00 » 20:33
09/17/20
09/17
20:33
09/17/20
20:33
U

Unity Software

$0.00 /

+ (+0.00%)

The deal priced above the…

The deal priced above the $44.00-$48.00 range. Goldman Sachs and Credit Suisse acted as joint book running managers for the offering.

ShowHide Related Items >><<
  • 18
    Sep
U Unity Software
$0.00 /

+ (+0.00%)

U Unity Software
$0.00 /

+ (+0.00%)

Hot Stocks
Realty Income raises monthly cash dividend to 23.4c per share from 23.35c » 19:14
09/17/20
09/17
19:14
09/17/20
19:14
O

Realty Income

$64.06 /

-1.34 (-2.05%)

Realty Income Corporation…

Realty Income Corporation (Realty Income, NYSE: O), The Monthly Dividend Company(R), today announced its Board of Directors has declared an increase in the company's common stock monthly cash dividend to $0.2340 per share from $0.2335 per share. The dividend is payable on October 15, 2020 to shareholders of record as of October 1, 2020. This is the 108th dividend increase since Realty Income's listing on the NYSE in 1994. The ex-dividend date for October's dividend is September 30, 2020. The new monthly dividend represents an annualized dividend amount of $2.808 per share as compared to the current annualized dividend amount of $2.802 per share.

ShowHide Related Items >><<
O Realty Income
$64.06 /

-1.34 (-2.05%)

O Realty Income
$64.06 /

-1.34 (-2.05%)

07/02/20 Citi
Realty Income price target raised to $61 from $49 at Citi
06/30/20 Berenberg
Realty Income initiated with a Buy at Berenberg
06/11/20 Raymond James
Realty Income price target raised to $71 from $66 at Raymond James
06/10/20 Wells Fargo
Realty Income price target raised to $68 from $55 at Wells Fargo
O Realty Income
$64.06 /

-1.34 (-2.05%)

  • 27
    Feb
Hot Stocks
Superior Energy receives NYSE notice regarding continued listing standard » 19:08
09/17/20
09/17
19:08
09/17/20
19:08
SPN

Superior Energy

$0.94 /

+0.0551 (+6.26%)

Superior Energy Services…

Superior Energy Services announced that the company was notified by the New York Stock Exchange of its determination to commence proceedings to delist and suspend trading of the company's common stock due to failure to meet the NYSE's $15M, 30-trading day average market capitalization standard. The company anticipates that, effective September 18, 2020, its common stock will commence trading on the OTCQX Market under the symbol "SPNX". The company's transition to the OTCQX Market is not expected to affect the company's business operations.

ShowHide Related Items >><<
SPN Superior Energy
$0.94 /

+0.0551 (+6.26%)

SPN Superior Energy
$0.94 /

+0.0551 (+6.26%)

05/22/20 RBC Capital
Superior Energy downgraded to Underperform from Sector Perform at RBC Capital
03/19/20 Wolfe Research
Superior Energy downgraded to Underperform from Outperform at Wolfe Research
03/09/20 Evercore ISI
Superior Energy downgraded to In Line from Outperform at Evercore ISI
SPN Superior Energy
$0.94 /

+0.0551 (+6.26%)

Periodicals
Unity Software prices IPO above range at $52 per share, Bloomberg says  19:06
09/17/20
09/17
19:06
09/17/20
19:06
U

Unity Software

$0.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
  • 18
    Sep
U Unity Software
$0.00 /

+ (+0.00%)

Hot Stocks
iFresh announces cancellation of special meeting of shareholders » 19:00
09/17/20
09/17
19:00
09/17/20
19:00
IFMK

iFresh

$0.82 /

+ (+0.00%)

iFresh announced that its…

iFresh announced that its Board of Directors has determined to cancel the special meeting of its shareholders scheduled for September 18, 2020 at which the Company had been intending to seek approvals by the shareholders of the Series A Share Exchange Proposal, the Series B Share Exchange proposal, the Nasdaq Proposal, and the Adjournment Proposal. A new meeting date for the re-scheduled shareholders' meeting will be announced by the Company in the near future.

ShowHide Related Items >><<
IFMK iFresh
$0.82 /

+ (+0.00%)

Periodicals
Tencent's gaming assets draw White House scrutiny, Bloomberg says » 18:43
09/17/20
09/17
18:43
09/17/20
18:43
KKR

KKR

$35.39 /

-0.72 (-1.99%)

, DIS

Disney

$130.20 /

-1.91 (-1.45%)

, TCEHY

Tencent

$0.00 /

+ (+0.00%)

, SNE

Sony

$77.62 /

+0.635 (+0.82%)

The Trump administration…

The Trump administration has asked video game companies to hand over information about their data-security protocols involving China's Tencent (TCEHY), Bloomberg's Jenny Leonard, Saleha Mohsin, and David McLaughlin report, citing people familiar with the matter. The Committee on Foreign Investment in the U.S., which is chaired by the Treasury Department, has issued letters to gaming entities, including "Fortnite" creator Epic Games and "League of Legends" creator Riot Games, to inquire about their security protocols in handling Americans' personal information, the authors say. Tencent owns Riot and a 40% interest in Epic, the authors note. The Fly notes that other investors in Epic include Disney (DIS), KKR (KKR), and Sony (SNE). Reference Link

ShowHide Related Items >><<
TCEHY Tencent
$0.00 /

+ (+0.00%)

SNE Sony
$77.62 /

+0.635 (+0.82%)

KKR KKR
$35.39 /

-0.72 (-1.99%)

DIS Disney
$130.20 /

-1.91 (-1.45%)

KKR KKR
$35.39 /

-0.72 (-1.99%)

08/05/20 Citi
Citi adds KKR to U.S. Focus List, ups price target to $47.50
07/09/20 Keefe Bruyette
KKR price target raised to $41 from $34 at Keefe Bruyette
06/29/20 Wells Fargo
CyrusOne CEO appointment could reignite sale speculation, says Wells Fargo
06/17/20 Piper Sandler
KKR initiated with an Overweight at Piper Sandler
DIS Disney
$130.20 /

-1.91 (-1.45%)

09/14/20 Jefferies
ESPN deal positive for both Caesars and DraftKings, says Jefferies
09/14/20 Evercore ISI
ESPN deal could add up to material dollars for DraftKings, says Evercore
09/08/20
Fly Intel: Top five analyst upgrades
09/08/20 Deutsche Bank
Disney upgraded to Buy from Hold at Deutsche Bank
TCEHY Tencent
$0.00 /

+ (+0.00%)

08/13/20 Benchmark
Tencent price target raised to HK$575 from HK$560 at Benchmark
08/03/20 Morgan Stanley
Sohu.com named a Research Tactical Idea at Morgan Stanley
07/27/20 Barclays
Tencent price target raised to $75 from $63 at Barclays
07/14/20 Citi
Tencent price target raised to HK$649 from HK$541 at Citi
SNE Sony
$77.62 /

+0.635 (+0.82%)

08/17/20
Loeb's Third Point buys Alibaba, makes a top holding, during second quarter
08/05/20 Oppenheimer
Sony price target raised to $100 from $70 at Oppenheimer
07/30/20
Fly Intel: Top five analyst initiations
07/29/20 Goldman Sachs
Sony resumed with a Conviction Buy at Goldman Sachs
TCEHY Tencent
$0.00 /

+ (+0.00%)

SNE Sony
$77.62 /

+0.635 (+0.82%)

KKR KKR
$35.39 /

-0.72 (-1.99%)

DIS Disney
$130.20 /

-1.91 (-1.45%)

SNE Sony
$77.62 /

+0.635 (+0.82%)

KKR KKR
$35.39 /

-0.72 (-1.99%)

DIS Disney
$130.20 /

-1.91 (-1.45%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

KKR KKR
$35.39 /

-0.72 (-1.99%)

DIS Disney
$130.20 /

-1.91 (-1.45%)

SNE Sony
$77.62 /

+0.635 (+0.82%)

DIS Disney
$130.20 /

-1.91 (-1.45%)

Hot Stocks
Proofpoint CEO: We are executing well » 18:40
09/17/20
09/17
18:40
09/17/20
18:40
PFPT

Proofpoint

$103.20 /

-0.57 (-0.55%)

In an interview on…

In an interview on CNBC's Mad Money, Gary Steele said he is pleased with Q2 results. "We felt the share buyback was the best way to return capital to shareholders," he noted. "We feel we play a very important role in the stay at home economy. We are well positioned to take advantage of the broader work from home trend," Steele said.

ShowHide Related Items >><<
PFPT Proofpoint
$103.20 /

-0.57 (-0.55%)

PFPT Proofpoint
$103.20 /

-0.57 (-0.55%)

08/26/20 Wedbush
Proofpoint assumed with an Outperform at Wedbush
08/19/20
Fly Intel: Top five analyst upgrades
08/19/20 Morgan Stanley
Proofpoint upgraded to Overweight from Equal Weight at Morgan Stanley
07/31/20 Northland
Proofpoint price target raised to $153 from $145 at Northland
PFPT Proofpoint
$103.20 /

-0.57 (-0.55%)

Hot Stocks
Babcock & Wilcox to supply superheater components to U.S. power customer » 18:33
09/17/20
09/17
18:33
09/17/20
18:33
BW

Babcock & Wilcox

$2.50 /

+0.005 (+0.20%)

Babcock & Wilcox…

Babcock & Wilcox announced that its B&W Thermal segment will design, manufacture and supply new superheater components for a B&W Universal Pressure supercritical boiler at Luminant's Oak Grove Power Plant near Franklin, Texas. The plant provides low-emissions power to more than one million central Texas homes and businesses. Engineering is underway for the contract, which was awarded to B&W's subsidiary, The Babcock & Wilcox Company. Components will be manufactured in B&W's Monterrey, Mexico, facility. Material delivery to Oak Grove is scheduled for February 2021.

ShowHide Related Items >><<
BW Babcock & Wilcox
$2.50 /

+0.005 (+0.20%)

BW Babcock & Wilcox
$2.50 /

+0.005 (+0.20%)

Hot Stocks
DavidsTea obtains Claims Process Order for creditor claims » 18:27
09/17/20
09/17
18:27
09/17/20
18:27
DTEA

DavidsTea

$0.97 /

-0.006 (-0.62%)

DavidsTea announced that…

DavidsTea announced that the Quebec Superior Court issued a Claims Process Order establishing the claims procedures for the company's creditors under the Companies' Creditors Arrangement Act. The Order, among other things, sets 5:00 p.m. eastern time on November 6 as the time by which creditors of DavidsTea and of its wholly-owned U.S. subsidiary, must submit their claims to PwC, the Court-appointment Monitor. The Court also extended the stay of all proceedings against the company currently in effect to December 15.

ShowHide Related Items >><<
DTEA DavidsTea
$0.97 /

-0.006 (-0.62%)

DTEA DavidsTea
$0.97 /

-0.006 (-0.62%)

Hot Stocks
BeiGene presents Phase 3 data on tislelizumab and pamiparib » 18:17
09/17/20
09/17
18:17
09/17/20
18:17
BGNE

BeiGene

$263.10 /

+7.97 (+3.12%)

BeiGene announced the…

BeiGene announced the first reported data from Rationale 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer, or NSCLC, and the first reported data from the pivotal Phase 2 trial of its investigational PARP inhibitor pamiparib in advanced ovarian cancer at the European Society for Medical Oncology Virtual Congress 2020. Tislelizumab in combination with pemetrexed and platinum chemotherapy demonstrated "encouraging" results among advanced NSCLC patients with non-squamous histology, including a median progression-free survival of 9.7 months and an overall response rate of 57.4%. RATIONALE 304 is a Phase 3 clinical trial of tislelizumab in combination with pemetrexed and platinum chemotherapy as a first-line treatment for patients with stage IIIB or stage IV non-squamous NSCLC. The trial achieved the primary endpoint of progression-free survival with a median of 9.7 months in Arm A, vs. 7.6 months in the chemotherapy alone Arm B; higher objective response rate and disease control rate were achieved in patients who received tislelizumab in combination with chemotherapy - 57.4% and 89.2% in Arm A vs. 36.9% and 81.1% in Arm B; longer duration of response in patients who received tislelizumab in combination with chemotherapy, with a median of 8.5 months in Arm A vs. 6.0 months in Arm B; treatment of tislelizumab in combination with platinum and pemetrexed was generally well-tolerated, with no new safety signals identified. All patients in Arm A and 99.1% of patients in Arm B experienced at least one treatment-emergent adverse event; nine patients experienced a fatal TEAE. Preliminary results presented at ESMO 2020 were from a Phase 2 dose-expansion portion of a Phase 1/2 trial of pamiparib in patients with advanced ovarian cancer, fallopian cancer, and primary peritoneal cancer or advanced triple negative breast cancer enrolled a total of 113 patients in China. Pamiparib was generally tolerated, consistent in patients with PSOC and PROC, and similar to other PARP inhibitors; most common TEAEs included anemia, nausea, decreased neutrophil count and others. No myelodysplastic syndrome or significant complications potentially related to hematologic AEs were reported in the trial.

ShowHide Related Items >><<
BGNE BeiGene
$263.10 /

+7.97 (+3.12%)

BGNE BeiGene
$263.10 /

+7.97 (+3.12%)

08/07/20 Ladenburg
BeiGene price target raised to $268 from $232 at Ladenburg
08/06/20 Piper Sandler
BeiGene price target raised to $175 from $165 at Piper Sandler
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
BGNE BeiGene
$263.10 /

+7.97 (+3.12%)

BGNE BeiGene
$263.10 /

+7.97 (+3.12%)

On The Fly
Fly Intel: After-Hours Movers » 18:11
09/17/20
09/17
18:11
09/17/20
18:11
SNOA

Sonoma Pharmaceuticals

$7.71 /

-0.04 (-0.52%)

, JAX

J. Alexander's

$4.79 /

-0.005 (-0.10%)

, KZR

Kezar Life Sciences

$5.17 /

+0.26 (+5.30%)

, AHT

Ashford Hospitality

$1.99 /

-0.08 (-3.86%)

, IDA

Idacorp

$83.54 /

+0.63 (+0.76%)

, CKPT

Checkpoint Therapeutics

$3.49 /

-0.76 (-17.88%)

, WINT

Windtree Therapeutics

$7.08 /

+0.46 (+6.95%)

Check out this evening's…

ShowHide Related Items >><<
WINT Windtree Therapeutics
$7.08 /

+0.46 (+6.95%)

SNOA Sonoma Pharmaceuticals
$7.71 /

-0.04 (-0.52%)

KZR Kezar Life Sciences
$5.17 /

+0.26 (+5.30%)

JAX J. Alexander's
$4.79 /

-0.005 (-0.10%)

IDA Idacorp
$83.54 /

+0.63 (+0.76%)

CKPT Checkpoint Therapeutics
$3.49 /

-0.76 (-17.88%)

AHT Ashford Hospitality
$1.99 /

-0.08 (-3.86%)

SNOA Sonoma Pharmaceuticals
$7.71 /

-0.04 (-0.52%)

JAX J. Alexander's
$4.79 /

-0.005 (-0.10%)

KZR Kezar Life Sciences
$5.17 /

+0.26 (+5.30%)

06/04/20 H.C. Wainwright
Kezar Life Sciences price target raised to $12 from $9 at H.C. Wainwright
05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
AHT Ashford Hospitality
$1.99 /

-0.08 (-3.86%)

06/17/20
Fly Intel: Top five analyst upgrades
06/17/20 DA Davidson
Ashford Hospitality upgraded to Neutral from Underperform at DA Davidson
04/06/20 B. Riley FBR
Ashford Hospitality downgraded to Neutral from Buy at B. Riley FBR
03/10/20 DA Davidson
Ashford Hospitality downgraded to Underperform from Neutral at DA Davidson
IDA Idacorp
$83.54 /

+0.63 (+0.76%)

05/04/20 Sidoti
Idacorp upgraded to Buy on valuation at Sidoti
05/04/20 Sidoti
Idacorp upgraded to Buy from Neutral at Sidoti
03/18/20 BofA
Idacorp upgraded to Buy from Neutral at BofA
11/04/19 BofA
Idacorp upgraded to Neutral from Underperform at BofA/Merrill
CKPT Checkpoint Therapeutics
$3.49 /

-0.76 (-17.88%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
04/13/20 B. Riley FBR
AstraZeneca study halt has positive read-through to Fortress, says B. Riley FBR
12/27/19 Lake Street
Checkpoint Therapeutics price target lowered to $8 from $12 at Lake Street
10/17/19 Lake Street
Checkpoint Therapeutics shares reflect 'valuation disconnect,' says Lake Street
WINT Windtree Therapeutics
$7.08 /

+0.46 (+6.95%)

06/26/20
Fly Intel: Top five analyst initiations
06/26/20 Ladenburg
Windtree Therapeutics initiated with a Buy at Ladenburg
KZR Kezar Life Sciences
$5.17 /

+0.26 (+5.30%)

IDA Idacorp
$83.54 /

+0.63 (+0.76%)

CKPT Checkpoint Therapeutics
$3.49 /

-0.76 (-17.88%)

  • 09
    Jun
  • 20
    May
  • 31
    Jan
  • 20
    Nov
AHT Ashford Hospitality
$1.99 /

-0.08 (-3.86%)

SNOA Sonoma Pharmaceuticals
$7.71 /

-0.04 (-0.52%)

KZR Kezar Life Sciences
$5.17 /

+0.26 (+5.30%)

KZR Kezar Life Sciences
$5.17 /

+0.26 (+5.30%)

Hot Stocks
Air Lease announces delivery of one new Airbus A350-1000 jet » 18:01
09/17/20
09/17
18:01
09/17/20
18:01
EADSY

Airbus

$0.00 /

+ (+0.00%)

, AL

Air Lease

$32.65 /

-0.3801 (-1.15%)

Air Lease Corporation…

Air Lease Corporation (AL) announced the delivery of one new Airbus (EADSY) A350-1000 aircraft on long-term lease to Virgin Atlantic. Powered by Trent XWB-97 engines, this aircraft is the first of four A350-1000s confirmed to deliver to the airline from ALC's order book with Airbus. "We are pleased to announce this first new A350-1000 aircraft delivery to Virgin Atlantic today," said Steven F. Udvar-Hazy, Executive Chairman of Air Lease Corporation. "Our A350-1000s will replace Virgin Atlantic's Boeing 747 aircraft on routes from London across the Atlantic to modernize the airline's long-haul fleet."

ShowHide Related Items >><<
EADSY Airbus
$0.00 /

+ (+0.00%)

AL Air Lease
$32.65 /

-0.3801 (-1.15%)

EADSY Airbus
$0.00 /

+ (+0.00%)

09/17/20 Credit Suisse
Airbus price target raised to EUR 106 from EUR 78 at Credit Suisse
09/09/20
Fly Intel: Top five analyst downgrades
09/09/20 Morgan Stanley
Airbus downgraded to Equal Weight from Overweight at Morgan Stanley
08/10/20 JPMorgan
Airbus price target lowered to EUR 50 from EUR 54 at JPMorgan
AL Air Lease
$32.65 /

-0.3801 (-1.15%)

06/01/20 BofA
AerCap downgraded to Neutral from Buy at BofA
05/26/20 JPMorgan
JPMorgan upgrades Fly Leasing with stock rally lagging peers
05/11/20 Deutsche Bank
Air Lease price target lowered to $36 from $45 at Deutsche Bank
EADSY Airbus
$0.00 /

+ (+0.00%)

AL Air Lease
$32.65 /

-0.3801 (-1.15%)

EADSY Airbus
$0.00 /

+ (+0.00%)

AL Air Lease
$32.65 /

-0.3801 (-1.15%)

EADSY Airbus
$0.00 /

+ (+0.00%)

Earnings
Steel Dynamics sees Q3 adjusted EPS 46c-50c, consensus 38c » 18:01
09/17/20
09/17
18:01
09/17/20
18:01
STLD

Steel Dynamics

$31.26 /

+0.81 (+2.66%)

Third quarter 2020…

Third quarter 2020 earnings from the company's steel operations are expected to be lower than sequential second quarter results, due to metal spread compression more than offsetting increased shipments driven by improved automotive and strong construction demand. Average realized quarterly flat roll steel product pricing is expected to decrease during the quarter based in part on lagging price-indexed contracts, offsetting the benefit of lower average scrap costs. However, flat roll steel pricing has stabilized and improved during the second half of the third quarter, supported by customer demand and raw material pricing. As domestic steel production improved in the third quarter from the trough experienced in the sequential second quarter, ferrous scrap demand also strengthened. Based on significantly higher scrap shipments, third quarter earnings from the company's metals recycling operations are expected to be meaningfully better than sequential second quarter results. Construction continues to show its resiliency. The customer order backlog for the company's steel fabrication platform remains strong, and customers are optimistic concerning non-residential construction projects. Third quarter 2020 earnings from the company's steel fabrication operations are expected to be at, or near, record results, based on anticipated record shipments and margin expansion, as product pricing is expected to improve while steel input costs decrease.

ShowHide Related Items >><<
STLD Steel Dynamics
$31.26 /

+0.81 (+2.66%)

STLD Steel Dynamics
$31.26 /

+0.81 (+2.66%)

07/29/20 Deutsche Bank
Steel Dynamics price target raised to $31 from $27 at Deutsche Bank
06/19/20 BMO Capital
Steel Dynamics price target raised to $29 from $24 at BMO Capital
06/08/20 Citi
Commercial Metals downgraded at Citi on valuation, scrap costs
05/13/20 KeyBanc
Steel Dynamics downgraded to Sector Weight from Overweight at KeyBanc
STLD Steel Dynamics
$31.26 /

+0.81 (+2.66%)

STLD Steel Dynamics
$31.26 /

+0.81 (+2.66%)

STLD Steel Dynamics
$31.26 /

+0.81 (+2.66%)

STLD Steel Dynamics
$31.26 /

+0.81 (+2.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.